Notícias e Atividades da NMD Pharma

Veja o organograma con seus 14 executivos principais

Biografias mais buscadas da NMD Pharma

• Thomas Holm Pedersen, Chief Executive Officer
• Mike Heffernan, Chairman of the Board
• Joao Ribas, Non-Executive Director

Recentes movimentos de executivos em NMD Pharma

• Ana De Vera, ingressou na Companhia como Chief Medical Officer  (Notícia publicada em 5 de setembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da NMD Pharma.

NMD Pharma possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de NMD Pharma

• NMD Pharma late-breaking oral presentation at MDA with top-line safety and efficacy data from the SYNAPSE-CMT Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease types 1 and 2. — NMD Pharma
• NMD Pharma SYNPASE-CMT Phase 2a Clinical Study Data Accepted for Late Breaking Oral Presentation at 2026 MDA Scientific & Medical Conference — NMD Pharma
• NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 — NMD Pharma
• NMD Pharma at J. P. Morgan Healthcare Conference 2026 — NMD Pharma
• NMD Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference — NMD Pharma
• NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer — NMD Pharma
• News — NMD Pharma
• News — NMD Pharma
• NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis — NMD Pharma
• NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model — NMD Pharma
• View more press releases Close

Redes sociais sobre NMD Pharma

• NMD Pharma na Wikipedia, Google News e Yahoo Finance
• NMD Pharma na LinkedIn, X (Twitter) e YouTube